(Q47931203)

English

High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation

scientific article published in May 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12732881

High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12732881

1 reference

based on heuristic

inferred from title

8

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12732881

author name string

Demirer T

1

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12732881

Uysal VA

2

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12732881

Ayli M

3

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12732881

Genc Y

4

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12732881

Ilhan O

5

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12732881

Koc H

6

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12732881

Dagli M

7

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12732881

Gunel N

9

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12732881

Fen T

10

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12732881

Dincer S

11

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12732881

Ustael N

12

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12732881

Yildiz M

13

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12732881

Ustun T

14

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12732881

Seyrek E

15

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12732881

Ozet G

16

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12732881

Muftuoglu O

17

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12732881

Akan H

18

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12732881

language of work or name

0 references

publication date

1 May 2003

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12732881

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12732881

31

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12732881

9

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12732881

755-761

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12732881

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1703918

0 references

The systemic administration of intravenous melphalan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703918

21 January 2018

Summary of results with triethylene thiophosphoramide.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703918

21 January 2018

High–dose melphalan with autologous bone marrow transplant treatment of poor prognosis tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703918

21 January 2018

A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703918

21 January 2018

Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703918

21 January 2018

Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703918

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703918

21 January 2018

High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703918

21 January 2018

High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703918

21 January 2018

Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703918

21 January 2018

High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703918

21 January 2018

Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703918

21 January 2018

Advanced breast cancer: high-dose chemotherapy and bone marrow autotransplants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703918

21 January 2018

Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703918

21 January 2018

High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703918

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703918

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703918

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703918

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703918

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703918

7 January 2021

based on heuristic

inferred from DOI database lookup

Collection of peripheral blood progenitor cells after the administration of cyclophosphamide, etoposide, and granulocyte-colony-stimulating factor: an analysis of 497 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703918

7 January 2021

based on heuristic

inferred from DOI database lookup

Regimen-related toxicity in patients undergoing bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703918

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703918

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703918

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703918

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703918

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703918

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1703918

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12732881

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 February 2018

http://europepmc.org/abstract/MED/12732881

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47931203&oldid=2176288642"